Development of Recombinant Immunoblot Assay Diagnostic Test Based on HIV-1 in Indonesia

Jeanne Elvia Christian, Silvia Tri Widyaningtyas, Budiman Bela

Abstract


Background: High mutation rates in HIV-1 could affect the accuracy of diagnostic tests. Therefore, recombinant antigen that has an immunodominant and conserved region from HIV-1 need to be developed to detect HIV-1 infection in Indonesia.

Materials and methods: The recombinant antigens comprise of Gag (p24), Pol and Env (gp41). Each antigens was expressed in the Escherichia coli expression system and purified using Ni-NTA chromatography. The reactivity of purified antigen against HIV antibodies was tested against a group of 50 HIV-positive plasma samples and 45 HIV-negative plasma samples in a recombinant immunoblot assay (RIBA) platform test. Moreover, 21 of 50 HIV-positive samples and 3 of 45 HIV-negative samples were also tested using HIV blot 2.2 to compare RIBA with a commercial western blot kit. Ten HBV-positive and 10 HCV-positive plasma samples were used to check cross-reactivity with HIV recombinant proteins in RIBA.

Results: All HIV-positive samples (100%) tested with RIBA were reactive towards Gag (p24), Pol, Env (gp41). Otherwise, 3 of 21 HIV-positive samples assayed with HIV blot 2.2 were not reactive to Pol protein. All HIV-negative samples tested with RIBA and 3 HIV-negative samples tested with HIV blot 2.2 did not produce any bands of HIV antigens. Few HBV and HCV samples showed reactivity towards HIV recombinant proteins.

Conclusion: Each recombinant protein, Gag (p24), Pol, Env (gp41), could be expressed and purified, as well as had reactivity to HIV-positive samples in RIBA test. Therefore, RIBA can be used as a diagnostic test to detect HIV-1 infection in Indonesia.

Keywords: diagnostic, HIV-1, immunodominant, recombinant immunoblot assay (RIBA)


Full Text:

PDF

References


Santoro MM, Perno CF. HIV-1 genetic variability and clinical implications. ISRN Microbiol. 2013; 2013: 481314, CrossRef.

Branson BM, Owen SM, Wesolowski LG, Bennett B, Werner BG, Wroblewski KE, et al. Laboratory Testing for The Diagnosis of HIV Infection: Updated Recommendations. Atlanta: Center for Disease Control and Prevention; 2014, CrossRef.

Mas A, Soriano V, Gutiérrez M, Fumanal F, Alonso A, González-Lahoz J. Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. Transfus Sci. 1997; 18(1): 63–9, CrossRef.

Hickman RK, Vallari A, Golden A, Lund J, Hackett J Jr, Brennan C, et al. Detection and differentiation of HIV-1 group O sera from HIV-1 group M and HIV-2 using recombinant antigens and peptides. J Virol Methods. 1998; 72(1): 43–9, CrossRef.

Johnson C, Fonner V, Sands A, Tsui S, Ford N, Wong V, et al. ANNEX 14. A Report on the Misdiagnosis of HIV Status. Geneva: World Health Organization; 2015, article.

World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendation for a Public Health Approach. Geneva: World Health Organization; 2021, article.

Menteri Kesehatan Republik Indonesia. Rencana Strategis Kementerian Kesehatan Tahun 2020-2024. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020, article.

Liu P, Tang L, Kong WH, Zhu ZR, Xiao P, Wang X, et al. Anti-HIV-1 antibodies based confirmatory results in Wuhan, China, 2012-2018. PLoS One. 2020; 15(9): e0238282, CrossRef.

Shams SF, Arian pour Z, Foomani FM, Noori HG. Evaluation of HIV indeterminate confirmatory test results of blood donors in northeast of Iran. Int J Med Lab. 2015; 2(1): 58–64, article.

Amechi BO, Osagie RN, Chikwendu CI. Evaluation of false positivity and cross reactivity in the investigation of human immunodeficiency virus (HIV) antibodies. Int J Commun Res 2006; 1(2): 54–9, article.

Shrestha LB, Yadav GK, Pradhan S, Sharma A, Pandit T, Chhetry R, et al. Co-infection of hepatitis B and hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal. PLoS One. 2022; 17(3): e0264791, CrossRef.

QIAGEN. The QIAexpressionistTM. 5th ed. Hilden: QIAGEN; 2003, article.

MP DiagnosticsTM. HIV Blot 2.2 Western Blot Assay: Instructions for Use. Singapore: MP Biomedicals Asia Pacific Pte Ltd.; 2016, article.

Fakruddin M, Mohammad Mazumdar R, Bin Mannan KS, Chowdhury A, Hossain MN. Critical factors affecting the success of cloning, expression, and mass production of enzymes by recombinant E. coli. ISRN Biotechnol. 2013; 2013: 590587, CrossRef.

Jia B, Jeon CO. High-throughput recombinant protein expression in Escherichia coli: Current status and future perspectives. Open Biol. 2016; 6(8): 160196, CrossRef.

Structural Genomics Consortium, China Structural Genomics Consortium, Northeast Structural Genomics Consortium, Gräslund S, Nordlund P, Weigelt J, et al. Protein production and purification. Nat Methods. 2008; 5(2): 135–46, CrossRef.

Remans K [Internet]. Heidelberg: European Molecular Biology Laboratory; ©2021. Protein Expression and Purification Core Facility [cited 2021 Dec 29]. Available from: https://www.embl.org/.

Li L, Xu T, Yang T, Zang L, Cheng W, Lin H, et al. Establishing a reentry procedure for human immunodeficiency virus screening-reactive donors in China. Transfusion. 2016; 56(1): 195–202, CrossRef.

Kline RL, McNairn D, Holodniy M, Mole L, Margolis D, Blattner W, et al. Evaluation of chiron HIV-1/HIV-2 recombinant immunoblot assay. J Clin Microbiol. 1996; 34(11): 2650–3, CrossRef.

Bio-Rad [Internet]. Hercules: Bio-Rad Laboratories, Inc; ©2021. Detection Methods [cited 2021 Dec 29]. Available from: http://www.bio-rad.com.




DOI: https://doi.org/10.21705/mcbs.v6i2.251

Indexed by:

               

               

          


Cell and BioPharmaceutical Institute